Exchange: NASDAQ·Updated 07:54 PM EDT

PSNL News

News
all
press releases
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
The trades put some of Ark's better-known holdings on the sell side, including AMD, Alphabet, and SpaceX, while its genomics-focused ARK Genomic Revolution ETF continued to add to biotech companies.
Stocktwits
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
The trades put some of Ark's better-known holdings on the sell side, including AMD, Alphabet, and SpaceX, while its genomics-focused ARK Genomic Revolution ETF continued to add to biotech companies.
Stocktwits
More News
This Gentex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday
Analysts downgraded Gentex, Personalis, Goosehead Insurance, cutting ratings and several price targets.read more...
Benzinga
Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders?
Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders? Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Sept. 9, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...
PR Newswire
Are PSNL, MKTX, BZH, HOWL Obtaining Fair Deals for their Shareholders?
Are PSNL, MKTX, BZH, HOWL Obtaining Fair Deals for their Shareholders? Are PSNL, MKTX, BZH, HOWL Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Sept. 4, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...
PR Newswire
SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future
ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major hurdle.
Stocktwits
What's Going On With Tempus AI Stock on Monday?
Tempus AI stock pulls back after a 20% surge as cancer data spotlights its Personalis deal, and FDA clears its pulmonary hypertension AI tool.read more...
Benzinga
TEM Stock On Track For Best Week In 4 Months Following Personalis Deal Spotlight
BTIG analyst Mark Massaro raised the firm’s price target on Tempus AI to $80 from $70 and kept a Buy rating.
Stocktwits
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
Personalis (PSNL) delivered earnings and revenue surprises of -20.00% and +30.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Personalis Reports Second Quarter Results and Recent Highlights
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended June 30, 2026, and highlighted recent business accomplishments. Second Quarter and Recent Strategic and Operational Highlights Secured...
Business Wire
Are BOW, UTZ, PSNL Obtaining Fair Deals for their Shareholders?
Are BOW, UTZ, PSNL Obtaining Fair Deals for their Shareholders? Are BOW, UTZ, PSNL Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 4, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...
PR Newswire

Advertisement|Remove ads.